From: Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis
Author, year | Method | Case | Non-case | Sensitivity (95% CI) | Specificity (95% CI) | ||
---|---|---|---|---|---|---|---|
+ | – | + | – | ||||
Supplemental US screening studies | |||||||
 Tagliafico, 2016 [21] | Supplemental US | 23 | 1 | 65 | 3142 | 0.96(0.77–1.00) | 0.98(0.97–0.98) |
 Kim, 2016 [22] | Supplemental US | 9 | 0 | 822 | 2340 | 1.00(0.63–1.00) | 0.74(0.72–0.76) |
 Weigert, 2015 [26] | Supplemental US | 24 | 15 | 411 | 9832 | 0.62(0.45–0.76) | 0.96(0.96–0.96) |
 Hwang, 2015 [25] | Supplemental US | 8 | 1 | 92 | 1626 | 0.89(0.51–0.99) | 0.95(0.93–0.96) |
 Moon, 2015 [24] | Supplemental US | 4 | 0 | 619 | 1382 | 1.00(0.40–1.00) | 0.69(0.67–0.71) |
 Parris, 2013 [28] | Supplemental US | 10 | 0 | 171 | 5338 | 1.00(0.66–1.00) | 0.97(0.96–0.97) |
 Girardi, 2013 [27] | Supplemental US | 41 | 0 | 381 | 21,709 | 1.00(0.89–1.00) | 0.98(0.98–0.98) |
 Leong, 2012 [32] | Supplemental US | 2 | 0 | 12 | 127 | 1.00(0.20–1.00) | 0.91(0.85–0.95) |
 Hooley, 2012 [31] | Supplemental US | 3 | 0 | 150 | 495 | 1.00(0.31–1.00) | 0.77(0.73–0.80) |
 Corsetti, 2011 [33] | Supplemental US | 32 | 8 | 363 | 6821 | 0.80(0.64–0.90) | 0.95(0.94–0.95) |
 Youk, 2011 [34] | Supplemental US | 10 | 1 | 41 | 394 | 0.91(0.57–1.00) | 0.91(0.87–0.93) |
 Brancato, 2007 [36] | Supplemental US | 2 | 0 | 106 | 5119 | 1.00(0.20–1.00) | 0.98(0.98–0.98) |
Joint screening studies | |||||||
 Dong, 2017 [9] | Primary MAM | 84 | 15 | 604 | 31,215 | 0.85(0.76–0.91) | 0.98(0.98–0.98) |
 | Primary US | 61 | 38 | 389 | 31,430 | 0.62(0.51–0.71) | 0.99(0.99–0.99) |
 Ohuchi, 2016 [10] | Primary MAM | 117 | 85 | 2300 | 33,547 | 0.58(0.51–0.65) | 0.94(0.93–0.94) |
 | Primary US | 143 | 59 | 2289 | 33,558 | 0.71(0.64–0.77) | 0.94(0.93–0.94) |
 Berg, 2016 [11] | Primary MAM | 59 | 52 | 700 | 6662 | 0.53(0.43–0.63) | 0.90(0.90–0.91) |
 | Primary US | 58 | 53 | 1012 | 6350 | 0.52(0.43–0.62) | 0.86(0.85–0.87) |
 Shen, 2015 [23] | Primary MAM | 8 | 6 | 3 | 6913 | 0.57(0.30–0.81) | 1.00(1.00–1.00) |
 | Primary US | 14 | 0 | 6 | 6910 | 1.00(0.73–1.00) | 1.00(1.00–1.00) |
 Brem, 2015 [39] | Primary MAM | 82 | 30 | 2219 | 12,987 | 0.73(0.64–0.81) | 0.85(0.85–0.86) |
 | Primary US | 95 | 17 | 2656 | 12,550 | 0.85(0.77–0.91) | 0.83(0.82–0.83) |
 Huang, 2012 [30] | Primary MAM | 28 | 5 | 48 | 2947 | 0.85(0.67–0.94) | 0.98(0.98–0.99) |
 | Primary US | 24 | 9 | 19 | 2976 | 0.73(0.54–0.86) | 0.99(0.99–1.00) |
 Kelly, 2010 [40] | Primary MAM | 23 | 34 | 36 | 4326 | 0.40(0.28–0.54) | 0.99(0.99–0.99) |
 | Primary US | 38 | 19 | 61 | 4301 | 0.67(0.53–0.78) | 0.99(0.98–0.99) |
 Wilczek, 2016 [38] | Primary MAM | 7 | 4 | 16 | 1641 | 0.64(0.32–0.88) | 0.99(0.98–0.99) |
 | Primary US | 11 | 0 | 27 | 1630 | 1.00(0.68–1.00) | 0.98(0.98–0.99) |
 Venturini, 2013 [29] | Primary MAM | 12 | 2 | 99 | 1553 | 0.86(0.56–0.97) | 0.94(0.93–0.95) |
 | Primary US | 2 | 12 | 8 | 813 | 0.14(0.03–0.44) | 0.99(0.98–1.00) |
 Weinstein, 2009 [35] | Primary MAM | 7 | 13 | 37 | 512 | 0.35(0.16–0.59) | 0.93(0.91–0.95) |
 | Primary US | 3 | 17 | 36 | 511 | 0.15(0.04–0.39) | 0.93(0.91–0.95) |
 Honjo, 2007 [37] | Primary MAM | 8 | 5 | 271 | 3259 | 0.62(0.32–0.85) | 0.92(0.91–0.93) |
 | Primary US | 7 | 6 | 158 | 3372 | 0.54(0.26–0.80) | 0.96(0.95–0.96) |